Course Description
About AAPP Toolkits
AAPP toolkits highlight both the evidence base available as well as strategies of clinical decision making used by expert psychiatric pharmacist clinicians. The content reflects the views and practice of the authors as substantiated with evidence-based facts as well as opinion and experience. Toolkits are peer reviewed by psychiatric pharmacists. Authors and AAPP review and update toolkits annually and strive to use up-to-date, non-stigmatizing language. Terminology does evolve rapidly and often regionally such that there may be differences between reader experiences and expectations and those of the author(s). AAPP members receive complimentary, continuous access to toolkits. Non-members can purchase for a fee for a period of 3 months.
Self-reported opioid misuse within the past year occurred in almost 10 million participants over the age of 12 who participated in the 2020 National Survey on Drug Use and Health. In the same survey, 2.7 million self-reported a diagnosis of opioid use disorder, approximately 700,000 individuals reported a heroin related substance use disorder, and about 2.3 million participants reported a prescription pain reliever substance use disorder.
The true incidence of opioid use disorder is unknown and is likely underestimated. Pharmacists can be advocates throughout the spectrum of treatment, from screening for an opioid use disorder and to management of medications for opioid use disorder (MOUD).
The toolkit provides quick tips and guideline summaries in the following areas of opioid use disorder:
- Withdrawal
- Medications for Treatment
- Overdose Prevention Education and Treatment
- Special Populations
- Co-Occurring Disorders
- Harm Reduction Strategies
- References
Authored by AAPP members Cassandra Davis, PharmD, BCPS, BCPP, and Natalie Valentino, PharmD, BCPP, this guide is intended to highlight both the evidence base available as well as strategies of clinical decision making used by expert clinicians.